For the quarter ending 2025-09-30, SNTI had -$9,322K decrease in cash & cash equivalents over the period. -$9,446K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -46,971 | - |
| Stock-based compensation | 1,551 | 2,730 |
| Depreciation | 904 | 1,840 |
| Change in fair value-Gene Fab Notes Receivable | 0 | 0 |
| Change in fair value-Gene Fab Economic Share | 0 | - |
| Change in fair value-Gene Fab Option | 0 | - |
| Loss on sale of property and equipment - related party | 0 | 0 |
| Impairment of long-lived assets | 0 | - |
| Other non-cash charges | 0 | 39 |
| Accounts receivable-Nonrelated Party | -12 | - |
| Accounts receivable-Related Party | -49 | - |
| Prepaid expenses and other assets-Related Party | -4,573 | - |
| Prepaid expenses and other assets-Nonrelated Party | -217 | - |
| Operating lease right-of-use assets | -1,687 | - |
| Accounts payable | 570 | - |
| Accrued expenses and other current liabilities | 308 | - |
| Operating lease liabilities | -3,418 | - |
| Genefab sublease deferred income - related party | -660 | - |
| Other non-current liabilities | 0 | - |
| Net cash used in operating activities | -9,446 | -27,123 |
| Purchases of property and equipment | 0 | 196 |
| Proceeds from sale of property and equipment | 0 | 12 |
| Net cash provided by (used in) investing activities | 0 | -184 |
| Proceeds from cirm grant | 0 | 2,520 |
| Proceeds from issuance of common stock related to atm, net of commissions | - | 534 |
| Proceeds from issuance of common stock-A2025ATMAgreement | 670 | - |
| Payment of issuance costs | 12 | 2,457 |
| Proceeds from issuance of common stock-Common Stock Purchase Agreement | 0 | - |
| Net cash provided by financing activities | 124 | 597 |
| Net decrease in cash, cash equivalents, and restricted cash | -9,322 | -26,710 |
| Cash and cash equivalents at beginning of period | 51,815 | - |
| Cash and cash equivalents at end of period | 15,783 | - |
Senti Biosciences, Inc. (SNTI)
Senti Biosciences, Inc. (SNTI)